Cognizin® (Citicoline)
C₁₄H₂₆N₄O₁₁P₂
Also known as: Citicoline, CDP-Choline, Cytidine Diphosphate-Choline, Cognizin®
Disclaimer: This information is for educational purposes only and is not intended as medical advice. Consult a healthcare professional before starting any supplement regimen.
Molecular Profile
C₁₄H₂₆N₄O₁₁P₂
488.32 g/mol
[[(2R,3S,4R,5R)-5-(4-Amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)ethyl phosphate
987-78-0
Overview
Citicoline (cytidine-5'-diphosphocholine, CDP-choline) is a naturally occurring compound present in every cell of the body, playing a critical role in cellular metabolism. As a supplement, it provides both cytidine (which converts to uridine) and choline — two building blocks essential for brain health. Citicoline is unique among choline sources because it supports two pathways simultaneously: acetylcholine synthesis for neurotransmission and phosphatidylcholine synthesis for neuronal membrane integrity. Cognizin® is a patented, clinically studied form of citicoline produced through a fermentation process. In many countries, citicoline is an approved pharmaceutical for stroke recovery and cognitive disorders. Its dual mechanism of action and extensive safety profile make it one of the most well-researched nootropic compounds available.
Mechanism of Action
Citicoline is hydrolyzed in the intestine to cytidine and choline, which are absorbed separately and recombined in the brain. The choline component serves as a precursor for acetylcholine synthesis and the Kennedy pathway of phosphatidylcholine (PC) production, which is critical for maintaining neuronal membrane structure. The cytidine is converted to uridine, which supports RNA synthesis and synaptic function. Citicoline also enhances mitochondrial function and increases brain ATP levels, supporting cellular energy metabolism. Additionally, it may upregulate sirtuin 1 (SIRT1) expression, providing neuroprotective effects, and has been shown to increase frontal lobe bioenergetics as measured by phosphorus MR spectroscopy.
Benefits & Evidence
Memory & Cognitive Function
Clinical studies in healthy adults show citicoline may improve memory performance, attention, and cognitive processing. Cognizin® 500mg/day improved attention and psychomotor speed in adolescents and adults.
Brain Energy Metabolism
Citicoline increases brain ATP levels and phosphocreatine concentrations, as demonstrated by phosphorus MR spectroscopy studies. This enhanced bioenergetic status may underlie improved cognitive function.
Neuroprotection & Brain Health
Extensive research, including comprehensive reviews, supports citicoline's neuroprotective properties. It helps maintain neuronal membrane integrity through phospholipid synthesis and has been studied extensively in stroke recovery and age-related cognitive decline.
Attention & Focus
A study in healthy adult women found Cognizin® 250-500mg/day for 28 days significantly improved attentional performance and reduced errors of omission on CPT-II testing.
Phospholipid Synthesis Support
Citicoline directly supports the Kennedy pathway of phosphatidylcholine biosynthesis, the primary mechanism for maintaining the structural and functional integrity of neuronal membranes throughout life.
Dosage & Timing
250-500mg
1-2x daily
Morning, with or without food
250mg — 1000mg
Note: Cognizin® has been studied at 250-500mg/day in healthy populations. Higher doses (1000-2000mg/day) are used in clinical settings for stroke recovery and cognitive disorders. Effects on brain energy can be detected acutely, but full cognitive benefits may take 2-4 weeks to manifest.
Safety Profile
Side Effects
- Insomnia (if taken late in the day)
- Headache
- Digestive issues (nausea, diarrhea)
- Rare: restlessness or overstimulation
Interactions
- Levodopa (citicoline may enhance levodopa's effects)
- Anticholinergic drugs (may counteract citicoline's cholinergic effects)
- Meclofenoxate and other nootropics (may have additive cholinergic effects)
Contraindications
- Pregnancy and breastfeeding (insufficient data despite generally favorable safety profile)
- Hypersensitivity to citicoline or any component
References & Sources
Improved attentional performance following citicoline administration in healthy adult women
McGlade E, Locatelli A, Hardy J, et al.
Food and Nutrition Sciences (2012)
Cognizin® 250-500mg/day for 28 days significantly improved attentional performance (fewer CPT-II omission errors) in healthy women aged 40-60.
DOI: 10.4236/fns.2012.36103 ↗Citicoline increases brain phosphodiesters and decreases beta-NTP response to a cognitive task: an in vivo 31P-MRS study
Silveri MM, Dikan J, Ross AJ, et al.
NMR in Biomedicine (2008)
Citicoline 500mg/day for 6 weeks increased frontal lobe phosphocreatine (+7%) and beta-NTP (ATP, +14%) levels measured by 31P-MRS.
DOI: 10.1002/nbm.1281 ↗Citicoline: pharmacological and clinical review, 2010 update
Secades JJ
Revista de Neurología (2011)
Comprehensive review of citicoline's pharmacology, confirming neuroprotective properties, membrane-stabilizing effects, and cognitive benefits across multiple clinical settings.
DOI: 10.33588/rn.52S02.2010788 ↗Citicoline in vascular cognitive impairment and vascular dementia after stroke
Alvarez-Sabín J, Román GC
Stroke (2011)
Review demonstrating citicoline's role in supporting cognitive recovery and neuroprotection following cerebrovascular events.
DOI: 10.1161/STROKEAHA.110.606509 ↗CDP-choline (citicoline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly
Fioravanti M, Yanagi M
Cochrane Database of Systematic Reviews (2005)
Cochrane review finding positive effects of citicoline on memory and behavior in elderly patients with cognitive deficits, though noting need for larger trials.
DOI: 10.1002/14651858.CD000269.pub3 ↗